Compare Abbott Laboratories (ABT) vs LYFT Inc (LYFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs LYFT Inc — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while LYFT Inc trades at $15.03 (market cap $5.86B). The key difference: Abbott Laboratories is far larger — about 28.5× LYFT Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| ABT | LYFT | |
|---|---|---|
Market Cap | $166.94B | $5.86B |
Sector | Health | Industrials |
52-Week High | $136.62 | $24.57 |
52-Week Low | $82.57 | $12.65 |
Enterprise Value | $193.69B | $5.40B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Lyft trades at $15.44, up 0.46% today, with a bullish technical signal from moving averages and oscillators. The company shows strong profitability with 43.82% net income margin and robust cash flow generation of $1.17B from operations in 2025. Recent management changes include the appointment of Senthil Padmanabhan as CTO effective July 2026, signaling continued operational focus.
Lyft presents an attractive valuation with P/E of 2.25 and P/S of 0.97, trading below the $18.25 consensus price target. However, mixed earnings performance and competitive pressures from Uber require monitoring. The stock offers upside potential but faces execution risks in the evolving ridesharing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
